8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A critical appraisal of the SUSTAIN-6 cardiovascular outcomes trial for semaglutide, covering enrollment biases, statistical design concerns, generalizability gaps, and what post-publication commentary revealed.
A deep-dive into SUSTAIN-6's trial design, randomization, blinding, endpoint definitions, statistical framework, and the methodological choices that shape how the 26% MACE reduction should actually be interpreted.
Deep-dive into cost-effectiveness analyses derived from the SUSTAIN-6 cardiovascular outcomes trial of semaglutide, including cost per QALY estimates, payer coverage considerations, and real-world pricing dynamics.
SUSTAIN-6 had no randomized long-term extension. See what its post hoc analyses, SELECT, and FLOW add about cardiovascular, kidney, and retinopathy outcomes.
A deep-dive into the SUSTAIN-6 trial results for semaglutide injectable, covering primary MACE endpoint effect sizes, secondary outcomes, subgroup analyses, and the time-course pattern of cardiovascular benefit in type 2 diabetes.
Deep-dive into SUSTAIN-6 pre-specified and post-hoc subgroup analyses for semaglutide injectable, examining differential MACE reduction by age, sex, BMI, baseline HbA1c, renal function, and cardiovascular history in type 2 diabetes.
A deep-dive into the SUSTAIN-6 cardiovascular outcomes trial for semaglutide in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
A deep-dive into the SUSTAIN-6 trial and how its 26% MACE reduction with semaglutide reshaped prescribing guidelines, cardiology referrals, and GLP-1 use beyond glycemic control in type 2 diabetes.